Clinical Trials

97 enrolled 43 charts

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT03332017 2026-02-18

ROSEWOOD

217 enrolled 23 charts 1 FDA

Lymphoma, Follicular

NCT03779113 2026-02-18

An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma

Phase 1 Terminated

69 enrolled 47 charts

Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell

NCT04569032 2026-02-18

A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression

82 enrolled 13 charts

Phase 2 Active not recruiting

Lymphoma, T-Cell, Peripheral

NCT02213926 2026-02-10

An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma

124 enrolled 10 charts 1 FDA

Lymphoma, Mantle-Cell

NCT02029443 2026-02-06

ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia

306 enrolled 26 charts

Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic

NCT02970318 2026-02-06

A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL

310 enrolled 18 charts 1 FDA

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04849416 2026-02-06

A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia)

87 enrolled 19 charts

Leukemia, Lymphoid, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT04809467 2026-02-04

topMIND

Phase 1/2 Terminated

54 enrolled 23 charts

Leukemia, Lymphoma, Non-Hodgkin, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT06509477 2026-02-03

Effectiveness and Safety Comparison of Lunaphil Ultra (Hyaluronic Acid, by Espad Pharmed Co.) Versus Juvederm Ultra 4® (Hyaluronic Acid, by Allergan Co.) in Nasolabial Folds (NLFs) Management

Phase NA Completed

104 enrolled 9 charts

Lymphoma, Follicular

NCT03932331 2026-01-29

Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies

105 enrolled 34 charts

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT05222555 2026-01-16

MINDway

53 enrolled 14 charts

Lymphoma, Large B-Cell, Diffuse

NCT04063215 2026-01-15

A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy for the Treatment of Traumatic Brain Injury and Hypoxic-Ischemic Encephalopathy

24 enrolled 67 charts

Brain Injuries, Traumatic, Bronchiolitis Obliterans Syndrome, Cerebral Palsy, Lymphoma, Follicular, Trauma, Nervous System, Intracranial Hemorrhages, Stroke, Hypoxia-Ischemia, Brain

NCT02264613 2026-01-13

ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas

142 enrolled 30 charts

Lymphoma, Lymphoma, T-Cell, Peripheral

NCT02337829 2026-01-08

Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL

48 enrolled 12 charts

Chromosome 17 deletion, Leukemia, Lymphoma, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03570892 2026-01-06

BELINDA

331 enrolled 10 charts

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT05228470 2026-01-06

A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.

39 enrolled 15 charts

LymphoidPlasma cell

Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, Hemorrhagic Disorders, Immune System Diseases, Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Vascular Diseases, Hemostatic Disorders, Neoplasms, Plasma Cell

NCT05678998 2026-01-06

WTX-330 in Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma

Phase 1 Completed

25 enrolled 31 charts

Lymphoma, Non-Hodgkin, Neoplasms

NCT04307134 2025-12-31

Besponsa Post Marketing Surveillance Study

Completed

108 enrolled 39 charts

Burkitt Lymphoma, Hematologic Neoplasms

NCT01695005 2025-12-26

A Study of LY3039478 in Participants With Advanced Cancer

Phase 1 Completed

247 enrolled 53 charts

Lymphoma, Neoplasm Metastasis, Neoplasms

NCT05179603 2025-12-24

A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma (Master Protocol) [Pegathor Lymphoma 205]

Phase 2 Terminated

14 enrolled 15 charts

Lymphoma, Large B-Cell, Diffuse

NCT03105336 2025-12-23

ZUMA-5

159 enrolled 27 charts 1 FDA

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

NCT04182204 2025-12-22

POLARGO

Phase 3 Completed

270 enrolled 36 charts

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT04680052 2025-12-22

InMIND

654 enrolled 40 charts 1 FDA

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

NCT02362035 2025-12-11

KEYNOTE145

LymphoidOther hematologic neoplasmPlasma cell

161 enrolled 29 charts

Burkitt Lymphoma, Hodgkin Disease, Leukemia, Hairy Cell, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT03774082 2025-12-11

REACH 5

46 enrolled 21 charts

Phase 2 Active not recruiting

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease, Lymphoma, Follicular

NCT04703192 2025-12-09

Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)

155 enrolled 11 charts

Lymphoma, T-Cell, Peripheral, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT05923112 2025-12-05

BESPONSA Injection 1 mg Special Investigation

Completed

421 enrolled 18 charts

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05687032 2025-12-03

A Study of Inotuzumab Ozogamicin in Chinese Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

Phase 4 Completed

44 enrolled 14 charts

359 enrolled 27 charts 1 FDA

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03391466 2025-12-01

ZUMA-7

Phase 3 Completed

Phase 2 Active not recruiting

Lymphoma, Large B-Cell, Diffuse

NCT02180724 2025-11-26

An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia

107 enrolled 15 charts

Waldenstrom Macroglobulinemia

NCT02477696 2025-11-20

Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)

533 enrolled 18 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02979522 2025-11-10

A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma

59 enrolled 63 charts

445 enrolled 22 charts 1 FDA

Hodgkin Disease

NCT02242942 2025-11-06

Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia

Phase 3 Completed

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03010176 2025-10-29

MK-1454-001

Phase 1 Completed

156 enrolled 20 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Lymphoma

NCT04875195 2025-10-29

MK-3475-B68

66 enrolled 16 charts

Hodgkin Disease

NCT04035434 2025-10-24

A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)

Phase 1/2 Terminated

93 enrolled 27 charts